Want to see NRSN full AI Analyst Report?
Top Page
Neurosense Therapeutics Ltd.
(NASDAQ:NRSN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.40
▼(-2.20% Downside)
Action:Reiterated
Date:09/09/26
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative cash flow, and negative equity). Technicals add additional risk due to a clear downtrend versus key moving averages, while valuation provides limited support because losses make P/E less informative and there is no dividend yield data.
Positive Factors
PrimeC development efficiency
A redesigned development route could improve capital efficiency and shorten the path from existing evidence to potential commercialization. If executed successfully, the plan may preserve resources for pivotal work while producing a more complete regulatory package for PrimeC.
Negative Factors
Pre-revenue operating model
The absence of commercial revenue leaves the company dependent on clinical progress rather than operating earnings to support its business. Persistent and widening losses increase the funding required to reach potential approval and leave profitability highly contingent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
PrimeC development efficiency
A redesigned development route could improve capital efficiency and shorten the path from existing evidence to potential commercialization. If executed successfully, the plan may preserve resources for pivotal work while producing a more complete regulatory package for PrimeC.
Read all positive factors
Neurosense Therapeutics Ltd. (NRSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.29M
Dividend YieldN/A
Average Volume (3M)494.89K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding37,766,098
10 Day Avg. Volume548,073
30 Day Avg. Volume494,895
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-12.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.67Price Target Upside1526.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Neurosense Therapeutics Ltd. Business Overview & Revenue Model
Company Description
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading ...
How the Company Makes Money
As a clinical-stage biotechnology company, NeuroSense Therapeutics does not have publicly available information indicating recurring commercial revenue from approved products. The company’s funding has primarily been associated with typical pre-co...
Neurosense Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -89.00K | 0.00 |
| EBITDA | -11.11M | -9.88M | -9.64M | -12.23M | -2.88M |
| Net Income | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M |
Balance Sheet | |||||
| Total Assets | 1.03M | 4.58M | 3.19M | 7.71M | 11.43M |
| Cash, Cash Equivalents and Short-Term Investments | 166.00K | 3.38M | 2.64M | 7.09M | 11.06M |
| Total Debt | 170.00K | 73.00K | 142.00K | 211.00K | 0.00 |
| Total Liabilities | 2.59M | 1.99M | 4.94M | 2.09M | 2.42M |
| Stockholders Equity | -1.56M | 2.58M | -1.76M | 5.62M | 9.01M |
Cash Flow | |||||
| Free Cash Flow | -7.68M | -10.14M | -8.38M | -7.66M | -1.56M |
| Operating Cash Flow | -7.67M | -10.13M | -8.35M | -7.59M | -1.54M |
| Investing Cash Flow | -8.00K | 1.00K | 3.47M | -3.54M | -17.00K |
| Financing Cash Flow | 4.43M | 10.91M | 3.98M | 3.69M | 11.90M |
Neurosense Therapeutics Ltd. Technical Analysis
Neutral
0.41
Price Trends
0.55
Negative
0.67
Negative
0.79
Negative
Market Momentum
-0.03
Negative
57.05
Neutral
64.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Neutral. The current price of 0.41 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.55, and below the 200-day MA of 0.79, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 57.05 is Neutral, neither overbought nor oversold. The STOCH value of 64.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRSN.
Neurosense Therapeutics Ltd. Risk Analysis
Neurosense Therapeutics Ltd. disclosed 69 risk factors in its most recent earnings report. Neurosense Therapeutics Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If we fail to maintain compliance with Nasdaq's continued listing requirements, our shares may be delisted from the Nasdaq Capital Market. Q4, 2023
2.
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
3.
Environmental, social and corporate governance, or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. Q4, 2023
Neurosense Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $74.84M | -7.68 | -173.28% | ― | 65.22% | 24.92% | |
43 Neutral | $6.71M | -0.35 | -160.28% | ― | -84.26% | 14.73% | |
42 Neutral | $19.29M | -0.94 | 1070.23% | ― | ― | ― | |
42 Neutral | $72.60M | -1.33 | -61.55% | ― | ― | -59.74% | |
42 Neutral | $8.18M | -1.08 | -237.91% | ― | ― | 23.05% |
* Healthcare Sector Average
NRSN
Neurosense Therapeutics Ltd.
0.42
-0.75
-64.27%
TENX
Tenax Therapeutics
1.98
-4.02
-67.00%
CLGN
Collplant Holdings
3.58
-23.02
-86.54%
XCUR
Exicure
1.41
-2.74
-66.02%
NRXS
NeurAxis, Inc.
5.91
3.46
141.22%
Neurosense Therapeutics Ltd. Corporate Events
NeuroSense Shareholders Approve Flexible Reverse Share Split Authorization
Aug 27, 2026
On August 26, 2026, NeuroSense Therapeutics Ltd. held a special meeting of shareholders where investors approved authorizing the board to execute one or more reverse share splits of the company’s ordinary shares. The approved aggregate ratio...
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts
Aug 13, 2026
NeuroSense Therapeutics has released a CEO letter dated August 13, 2026, outlining preparations for PARAGON, its pivotal Phase 3 trial of PrimeC in ALS, following U.S. FDA clearance to enroll about 300 participants primarily in the United States. ...
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process
Aug 6, 2026
On August 6, 2026, NeuroSense Therapeutics reported that it has completed the Pre-NDS process with Health Canada for PrimeC, its lead ALS candidate, and is working toward filing a New Drug Submission in early December 2026. Meeting minutes from th...
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective
Jul 31, 2026
On July 31, 2026, NeuroSense Therapeutics Ltd. amended its Capital on Demand sales agreement with JonesTrading to align it with a newly effective Form F-3 shelf registration declared effective the same day by the U.S. Securities and Exchange Commi...
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split
Jul 31, 2026
NeuroSense Therapeutics Ltd. has called a Special Meeting of Shareholders for August 26, 2026, at its Ra’anana, Israel headquarters to seek approval for a significant change to its capital structure. Shareholders of record as of July 31, 202...
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS
Jul 22, 2026
NeuroSense Therapeutics, a late-stage clinical biotech developer of neurodegenerative disease treatments, is advancing its lead candidate PrimeC, a multi-pathway oral combination therapy targeting mechanisms such as neuroinflammation, oxidative st...
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3
Jun 29, 2026
On June 29, 2026, NeuroSense reported that its Phase 2b PARADIGM trial of PrimeC in ALS achieved its primary efficacy endpoint by delivering a statistically significant reduction in neuron-derived TDP-43 versus placebo, sustained and deepening ove...
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
Jun 25, 2026
On June 25, 2026, NeuroSense Therapeutics reported positive biomarker data from its Phase 2 RoAD proof-of-concept trial of PrimeC in Alzheimer’s disease, a randomized, double-blind, placebo-controlled study involving eight participants. Plas...
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC
Jun 11, 2026
NeuroSense Therapeutics Ltd., a late-clinical stage biotech focused on treatments for severe neurodegenerative diseases such as ALS and Alzheimer’s, is advancing PrimeC, an oral fixed-dose combination therapy designed to act on several key m...
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC
Jun 9, 2026
NeuroSense Therapeutics announced on June 9, 2026 that the Japan Patent Office has granted Japanese Patent 7857044 covering the composition and manufacturing process of PrimeC, its lead drug candidate for ALS, extending protection for the synchron...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.